PDF(Pubmed)
Abstract：
UNASSIGNED: Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort.
UNASSIGNED: KBP-2020 was a prospective cohort that included all patients diagnosed with LC in 2020, in nonacademic public hospital in France. Patient and tumour characteristics were described and compared with similarly designed cohorts in 2000 and 2010.
UNASSIGNED: In 2020, 82 centers included 8,999 patients diagnosed with LC. The proportion of women increased: 34·6% (3114/8999) compared to, 24·3% (1711/7051) and 16·0% (904/5667) in 2010 and 2000 (p<0·0001). The proportion of non-smokers was higher in 2020 (12·6%, 1129/8983) than in previous cohorts (10·9% (762/7008) in 2010; 7·2% (402/5586) in 2000, p<0·0001). In 2020, at diagnosis, 57·6% (4405/7648) of patients had a metastatic/disseminated stage non-small-cell lung cancer (NSCLC) (58·3% (3522/6046) in 2010; 42·6% (1879/4411) in 2000, p<0·0001). Compared with 2000 and 2010 data, early survival improved slightly. In 2020, 3-month mortality of NSCLC varied from 3·0% [2·2 - 3·8] for localized to 9·6% [8·1 - 11·0] for locally advanced to 29·2% [27·8 - 30·6] for metastatic and was 24·8% [22·3 - 27·3] for SCLC.
UNASSIGNED: To our knowledge KBP cohorts have been the largest, prospective, real-world cohort studies involving LC patients conducted in worldwide. The trend found in our study shows an increase in LC in women and still a large proportion of patients diagnosed at metastatic or disseminated stage.
UNASSIGNED: The study was promoted by the French College of General Hospital Pulmonologists with financial support of industrials laboratories.
UNASSIGNED: KBP-2020 was a prospective cohort that included all patients diagnosed with LC in 2020, in nonacademic public hospital in France. Patient and tumour characteristics were described and compared with similarly designed cohorts in 2000 and 2010.
UNASSIGNED: In 2020, 82 centers included 8,999 patients diagnosed with LC. The proportion of women increased: 34·6% (3114/8999) compared to, 24·3% (1711/7051) and 16·0% (904/5667) in 2010 and 2000 (p<0·0001). The proportion of non-smokers was higher in 2020 (12·6%, 1129/8983) than in previous cohorts (10·9% (762/7008) in 2010; 7·2% (402/5586) in 2000, p<0·0001). In 2020, at diagnosis, 57·6% (4405/7648) of patients had a metastatic/disseminated stage non-small-cell lung cancer (NSCLC) (58·3% (3522/6046) in 2010; 42·6% (1879/4411) in 2000, p<0·0001). Compared with 2000 and 2010 data, early survival improved slightly. In 2020, 3-month mortality of NSCLC varied from 3·0% [2·2 - 3·8] for localized to 9·6% [8·1 - 11·0] for locally advanced to 29·2% [27·8 - 30·6] for metastatic and was 24·8% [22·3 - 27·3] for SCLC.
UNASSIGNED: To our knowledge KBP cohorts have been the largest, prospective, real-world cohort studies involving LC patients conducted in worldwide. The trend found in our study shows an increase in LC in women and still a large proportion of patients diagnosed at metastatic or disseminated stage.
UNASSIGNED: The study was promoted by the French College of General Hospital Pulmonologists with financial support of industrials laboratories.
摘要：
UNASSIGNED：肺癌（LC）患者的长期变化难以评估。我们报告了法国KBP-2020现实生活队列的结果。
UNASSIGNED：KBP-2020是一个前瞻性队列，包括2020年在法国非学术公立医院诊断为LC的所有患者。描述了患者和肿瘤特征，并与2000年和2010年类似设计的队列进行了比较。
未经评估：2020年，82个中心包括8,999名诊断为LC的患者。女性比例增加：34%(3114/8999)，2010年和2000年为24·3%（1711/7051）和16·0%（904/5667）（p<0·0001）。2020年不吸烟者的比例更高(12.6%，1129/8983）比以前的队列（2010年为10·9%（762/7008）；2000年为7·2%（402/5586），p<0·0001）。2020年，在诊断时，57·6％（4405/7648）的患者患有转移性/播散期非小细胞肺癌（NSCLC）（2010年为58·3％（3522/6046）；2000年为42·6％（1879/4411），p<0·0001）。与2000年和2010年的数据相比，早期生存率略有改善。2020年，NSCLC的3个月死亡率从局部的3·0%[2·2-3·8]到局部晚期的9·6%[8·1-11·0]到转移性的29·2%[27·8-30·6]，SCLC为24·8%[22·3-27·3]。
未经评估：据我们所知，KBP队列是最大的，prospective,在全球范围内进行的涉及LC患者的真实世界队列研究.在我们的研究中发现的趋势表明，女性LC的增加，并且仍然有很大一部分被诊断为转移或扩散期的患者。
UNASSIGNED：该研究由法国综合医院肺科医师学院在工业实验室的财政支持下推广。
UNASSIGNED：KBP-2020是一个前瞻性队列，包括2020年在法国非学术公立医院诊断为LC的所有患者。描述了患者和肿瘤特征，并与2000年和2010年类似设计的队列进行了比较。
未经评估：2020年，82个中心包括8,999名诊断为LC的患者。女性比例增加：34%(3114/8999)，2010年和2000年为24·3%（1711/7051）和16·0%（904/5667）（p<0·0001）。2020年不吸烟者的比例更高(12.6%，1129/8983）比以前的队列（2010年为10·9%（762/7008）；2000年为7·2%（402/5586），p<0·0001）。2020年，在诊断时，57·6％（4405/7648）的患者患有转移性/播散期非小细胞肺癌（NSCLC）（2010年为58·3％（3522/6046）；2000年为42·6％（1879/4411），p<0·0001）。与2000年和2010年的数据相比，早期生存率略有改善。2020年，NSCLC的3个月死亡率从局部的3·0%[2·2-3·8]到局部晚期的9·6%[8·1-11·0]到转移性的29·2%[27·8-30·6]，SCLC为24·8%[22·3-27·3]。
未经评估：据我们所知，KBP队列是最大的，prospective,在全球范围内进行的涉及LC患者的真实世界队列研究.在我们的研究中发现的趋势表明，女性LC的增加，并且仍然有很大一部分被诊断为转移或扩散期的患者。
UNASSIGNED：该研究由法国综合医院肺科医师学院在工业实验室的财政支持下推广。
